Zimmer Biomet (NYSE:ZBH) Posts Earnings Results, Beats Estimates By $0.01 EPS

Zimmer Biomet (NYSE:ZBH) released its earnings results on Thursday. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01, RTT News reports. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. During the same period last year, the business posted $2.20 earnings per share. Zimmer Biomet updated its FY 2025 guidance to 8.150-8.350 EPS.

Zimmer Biomet Trading Down 3.3 %

ZBH stock traded down $3.59 during mid-day trading on Thursday, reaching $104.66. 1,526,851 shares of the stock traded hands, compared to its average volume of 1,703,455. The business has a 50-day moving average price of $107.75 and a two-hundred day moving average price of $108.20. The stock has a market capitalization of $20.83 billion, a PE ratio of 19.95, a PEG ratio of 1.88 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. Zimmer Biomet has a one year low of $100.67 and a one year high of $133.90.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.92%. The ex-dividend date of this dividend was Monday, December 30th. Zimmer Biomet’s payout ratio is 18.25%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ZBH. Wells Fargo & Company increased their price objective on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Royal Bank of Canada upped their price objective on Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a research note on Monday, November 4th. Truist Financial lifted their target price on Zimmer Biomet from $117.00 to $118.00 and gave the company a “hold” rating in a research note on Wednesday, December 18th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research note on Wednesday, January 29th. Finally, Raymond James reduced their price objective on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $124.11.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.